Amit Shah, MD
Clinical Cardiac Electrophysiology · Tuscaloosa, ALNPI 1275503948
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 49.5% of the total. Reporting peaked in 2023 at $16,355 and has fallen 59.3% since, to $6,662 in 2025.
Across 598 payments — averaging $76.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$23K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
- Abbott$2K
- Novartis$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Johnson & Johnson$585
- plus $3K from 24 others
What the payments were for
- Consulting fees$3,1257%
- Speaking & faculty fees$17,40038%
- Travel & lodging$15,78135%
- Food & beverage$9,38521%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 58 | $22,637 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 41 | $14,791 |
| Abbott | 34 | $2,054 |
| Novartis | 199 | $2,029 |
| Actelion Pharmaceuticals US, Inc. | 64 | $1,070 |
| Johnson & Johnson | 51 | $585 |
| Amgen | 44 | $577 |
| Merck | 15 | $284 |
| Sanofi-aventis U.S. LLC | 16 | $260 |
| Biosense Webster, Inc. | 15 | $242 |
| Cvrx, Inc. | 3 | $160 |
| Novo Nordisk | 7 | $146 |
| Gilead | 10 | $131 |
| Boehringer Ingelheim | 6 | $120 |
| Boston Scientific | 4 | $114 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Pfizer | 4 | $66 |
| Impulse Dynamics (USA) Inc. | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $53 |
| AstraZeneca | 3 | $41 |
| United Therapeutics Corporation | 3 | $33 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Irhythm Technologies, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Eisai Inc. | 1 | $23 |
| Abiomed | 1 | $22 |
| GSK | 1 | $16 |
| Lantheus Medical Imaging, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$14,250
- Micra$11,514
- EVERA MRI XT DR SURESCAN$1,488
- AVEIR$1,051
- Barostim Neo System$134
- SYMPLICITY G3$115
How this compares
$45,710 in reported general payments places this provider in the 75th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
See all clinical cardiac electrophysiology providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 772 | $748,650 |
| AdempasRiociguat | 31 | $437,603 |
| UptraviSelexipag | 14 | $298,002 |
| OpsumitMacitentan | 22 | $267,134 |
| XareltoRivaroxaban | 266 | $231,495 |
| MultaqDronedarone Hcl | 170 | $191,923 |
| EntrestoSacubitril/Valsartan | 165 | $190,413 |
| LetairisAmbrisentan | 13 | $158,599 |
| Ambrisentan | 21 | $84,087 |
| Repatha SureclickEvolocumab | 45 | $46,495 |
| CorlanorIvabradine Hcl | 22 | $14,125 |
| FarxigaDapagliflozin Propanediol | 11 | $13,955 |
| Flecainide Acetate | 236 | $12,462 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $9,069 |
| Metoprolol Succinate | 436 | $8,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $66 | $748,650772 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,070 | $565,13736 claims |
| BayerAdempas | $14 | $437,60331 claims |
| Johnson & JohnsonXarelto | $585 | $231,495266 claims |
| Sanofi-aventis U.S. LLCMultaq | $260 | $191,923170 claims |
| NovartisEntresto | $2,029 | $190,413165 claims |
| GileadLetairis | $131 | $158,59913 claims |
| AmgenCorlanor | $577 | $14,12522 claims |
| AstraZenecaFarxiga | $41 | $13,95511 claims |
| Esperion Therapeutics, Inc.Nexlizet | $75 | $9,06912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
Other clinical cardiac electrophysiology in Tuscaloosa
- Hugh McElderryBirmingham$725K
- Anil RajendraBirmingham$495K
- Gustavo MoralesBirmingham$171K
- William MaddoxBirmingham$159K
- Francis BennBirmingham$95K
- Terence DunnBirmingham$73K
- Thomas TurnageMobile$71K
- Ernest QuinMobile$65K
- Byron ColleyBirmingham$59K
- Jordan ChaissonMobile$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.